Table 2.
Comparison of clinical characteristics between groups with or without residual CT abnormalities
| No residual legions | Presence of residual legions | ||
|---|---|---|---|
| (n = 19) | (n = 17) | p value | |
| Age, years | 40 (34, 54) | 55 (48, 62) | 0.014 |
| Male, n (%) | 22.88 (21.51, 25.15) | 24.24 (23.42, 25.24) | 0.318 |
| BMI, kg/m2 | 11 (57.9%) | 10 (58.8%) | 1 |
| Drinking history, n (%) | 0 (0%) | 1 (5.9%) | 0.472 |
| Current smoker, n (%) | 0 (0%) | 4 (23.5%) | 0.04 |
| Hypertension, n (%) | 2 (10.5%) | 7 (41.2%) | 0.05 |
| Type 2 diabetes, n (%) | 1 (5.3%) | 3 (17.6%) | 0.325 |
| COPD/emphysema, n (%) | 1 (5.3%) | 1 (5.9%) | 0.933 |
| Duration from illness onset to hospital admission, days | 5 (2, 8) | 6 (4, 7) | 0.962 |
| Severe illness during hospitalization | 4 (21.1%) | 8 (47.1%) | 0.158 |
| Nasopharyngeal viral RNA shedding duration, days | 15 (12, 23) | 19 (13, 21) | 0.515 |
| Peak CT score during hospitalization | 6.5 (4, 9.5) | 9 (6, 13) | 0.301 |
| Corticosteroid treatment, n (%) | 11 (57.9%) | 13 (76.5%) | 0.302 |
| Secondary bacterial infection, n (%) | 0 (0%) | 5 (29.4%) | 0.016 |
| ICU admission, n (%) | 1 (5.3%) | 2 (11.8%) | 0.593 |
| HFNC, n (%) | 2 (10.5%) | 4 (23.5%) | 0.391 |
| Laboratory indicators on admission | |||
| Lymphocyte count (* 109/L) | 0.9 (0.6, 1.4) | 0.9 (0.5, 1.1) | 0.633 |
| D-dimer, mg/L | 318 (170, 425) | 328 (178, 477) | 0.666 |
| ALT, U/L | 26 (19, 53) | 22 (15, 27) | 0.109 |
| AST, U/L | 22 (18, 41) | 19 (17, 21) | 0.089 |
| CRP, mg/L | 10.33 (3.55, 27.87) | 20.94 (11.39, 68.3) | 0.096 |
| IL-6, pg/mL | 13.58 (5.63, 50.46) | 14.27 (5.29, 24.01) | 0.763 |
| ESR, mm/h | 27 (8, 42) | 27 (13, 74) | 0.31 |
| SaO2 | 98.5% (97.6%, 99.6%) | 96.9% (93.7%, 98.3%) | 0.004 |
| PFTs at 1-year follow-up# | |||
| FVC % | 100 (94, 106) | 95 (84, 102) | 0.096 |
| FEV1 % | 100 (93, 103) | 98 (87, 105) | 0.579 |
| PEF | 95 (69, 105) | 82 (69, 95) | 0.168 |
| FEV1/FVC | 82.3 (77.9, 85.1) | 82.4 (78.3, 84.7) | 0.987 |
| DLCO % | 113 (105, 124) | 112 (93, 121) | 0.375 |
| TLC % | 107 (96, 111) | 94 (83, 99) | 0.008 |
| RV % | 132 (121, 144) | 105 (95, 120) | < .0001 |
Kruskal-Wallis test for continuous variables or Fisher’s exact test for categorical variables was used for comparison between groups when applicable with p < 0.05 as significant
The occurrence data are shown as no. (%) unless otherwise indicated. Values indicate no. of positive results/total no. of patients with available assay results
The time data are shown as median data and inter quartile range data in brackets
#Pulmonary function tests were expressed as percent of the predicted value
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; ALT, Alanine aminotransferase. AST, Aspartate aminotransferase; ESR, Erythrocyte sedimentation rate; CRP, C-reaction protein; IL-6, interleukin-6; SaO2, oxygen saturation; HFNC, high flow nasal catheter oxygen therapy; PFTs, pulmonary function tests; FVC, forced vital capacity; FEV1, forced expiratory volume in the first 1 s of expiration; PEF, peak expiratory flow; DLCO, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; RV, residual volume